Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Antagonist muscle

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    19 result(s) found for: Antagonist muscle. Displaying page 1 of 1.
    EudraCT Number: 2006-006424-18 Sponsor Protocol Number: EC/2006/117/PGMS Start Date*: 2007-03-01
    Sponsor Name:University of Surrey
    Full Title: THE EFFECT OF RIMONABANT ON ENERGY EXPENDITURE, FATTY ACID METABOLISM, TRIACYLGLYCEROL METABOLISM AND BODY FAT DISTRIBUTION
    Medical condition: Obesity
    Disease: Version SOC Term Classification Code Term Level
    8.1 10029883 Obesity LLT
    Population Age: Adults Gender: Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-006042-41 Sponsor Protocol Number: NC3-project Start Date*: 2006-05-15
    Sponsor Name:Karolinska Institutet
    Full Title: Local treatment of craniomandibular myofascial pain with the 5-HT3 receptor antagonist granisetron. A randomized and double-blind study.
    Medical condition: Craniomandibular myalgia
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2007-000735-26 Sponsor Protocol Number: AGN/HO/SPA/001-191622 Start Date*: 2007-06-18
    Sponsor Name:Allergan Ltd.
    Full Title: A Multicentre, Double-Blind, Prospective, Randomised, European and Canadian Study to Evaluate Patient Outcomes and Costs of Managing Adults with Spasticity and Associated Focal Spasticity.
    Medical condition: Spasticity and Associated Focal Spasticity
    Disease: Version SOC Term Classification Code Term Level
    9.1 10041416 Spasticity LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) SE (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2022-001522-30 Sponsor Protocol Number: RIMOFATSCI-2 Start Date*: 2022-10-03
    Sponsor Name:Fundación Hospital Nacional de Parapléjicos
    Full Title: Effects of a CB1 receptor reverse antagonist/agonist (Rimonabant) on wandering ability in patients with incomplete spinal cord injuries
    Medical condition: Possibility of improving wandering in patients. The effects of Rimonabant on other functional measures will be assessed and it will be confirmed that it is a safe treatment in the study population.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-001069-18 Sponsor Protocol Number: 12/0533 Start Date*: 2013-07-11
    Sponsor Name:University College London (UCL)
    Full Title: MINeralocorticoid receptor antagonist pretreatment to MINIMISE reperfusion injury after ST-Elevation Myocardial Infarction(STEMI).
    Medical condition: Cardiovascular disease
    Disease: Version SOC Term Classification Code Term Level
    14.1 10007541 - Cardiac disorders 10007649 Cardiovascular disorder PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2019-003375-19 Sponsor Protocol Number: B8011006 Start Date*: 2020-07-20
    Sponsor Name:Pfizer Inc.
    Full Title: A Phase 3, Multinational, Randomized, Open-Label, Three Parallel-Arm Study of PF-06801591, an anti-PD-1 antibody, in Combination with Bacillus Calmette-Guerin (BCG Induction With or Without BCG Mai...
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10022877 Invasive bladder cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) GB (GB - no longer in EU/EEA) PT (Completed) BE (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2006-001767-31 Sponsor Protocol Number: 101105 Start Date*: 2007-03-21
    Sponsor Name:University of Sheffield
    Full Title: Investigation of the effect of Interleukin-1 receptor antagonist (IL-1ra) on markers of inflammation in non-ST elevation acute coronary syndromes
    Medical condition: We wish to investigate Acute coronary syndromes (ACS). These are caused by blockages in the main arteries that supply the heart as a result of a process called atherosclerosis. These blockages pr...
    Disease: Version SOC Term Classification Code Term Level
    8.1 10051592 Acute coronary syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2009-016537-98 Sponsor Protocol Number: SRT-2104-011 Start Date*: 2010-02-22
    Sponsor Name:Sirtris Pharmaceuticals Inc.
    Full Title: A Phase IIa, Randomized, Placebo-Controlled, Double-Blind Clinical Study to Assess the Safety, Tolerability and Activity of Oral SRT2104 Capsules Administered for 28 days to Subjects with Type 2 Di...
    Medical condition: Type II Diabetes Mellitus
    Disease: Version SOC Term Classification Code Term Level
    12.0 10045242 Type II diabetes mellitus LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2015-002396-18 Sponsor Protocol Number: 2015-602295-02 Start Date*: 2015-11-30
    Sponsor Name:Ethicare GmbH
    Full Title: ORODISPERSIBLE MINITABLETS OF ENALAPRIL IN YOUNG CHILDREN WITH HEART FAILURE DUE TO CONGENITAL HEART DISEASE
    Medical condition: Heart Failure due to Congenital Heart Disease
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004850 10010495 Congenital heart disease NOS LLT
    Population Age: Newborns, Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: HU (Completed) GB (Prematurely Ended) NL (Ongoing) AT (Completed) DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2014-002113-39 Sponsor Protocol Number: BAY88-8223/16298 Start Date*: 2014-10-29
    Sponsor Name:Bayer AG
    Full Title: A phase II randomized, double-blind, placebo-controlled trial of radium-223 dichloride versus placebo when administered to metastatic HER2 negative hormone receptor positive breast cancer subjects ...
    Medical condition: HER2 negative hormone receptor positive metastatic breast cancer with bone metastases treated with standard of care hormonal treatment.
    Disease: Version SOC Term Classification Code Term Level
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055113 Breast cancer metastatic PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Completed) ES (Completed) AT (Completed) NO (Completed) CZ (Completed) DK (Prematurely Ended) NL (Completed) SE (Completed) PL (Completed) FI (Completed) IE (Completed) FR (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2011-001201-27 Sponsor Protocol Number: P07038 Start Date*: 2011-11-07
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., USA
    Full Title: A randomized, controlled, parallel-group, double-blind trial of sugammadex or usual care (neostigmine or spontaneous recovery) for reversal of rocuronium- or vecuronium-induced neuromuscular blocka...
    Medical condition: not applicable
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) NL (Prematurely Ended) AT (Completed)
    Trial results: View results
    EudraCT Number: 2006-005361-19 Sponsor Protocol Number: 123-2006 Start Date*: 2007-03-09
    Sponsor Name:St Georges Hospital
    Full Title: Evaluation of the efficacy of the dual endothelin 1 receptor antagonist Bosentan in the treatment of Pulmonary Hypertension secondary to Chronic Obstructive Pulmonary Disease and in the treatment o...
    Medical condition: Pulmonary Hypertension secondary to Chronic Obstructive Pulmonary Disease and secondary to Sarcoid Patients devolop pulmonary hypertension for various reasons, two common causes are Chronic Obstru...
    Disease: Version SOC Term Classification Code Term Level
    8.1 10037400 Pulmonary hypertension LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2015-002150-12 Sponsor Protocol Number: DANSVIGT Start Date*: 2017-10-11
    Sponsor Name:Danish Society of Cardiology, Heart Failure Working Group
    Full Title: DanHeart (H-HeFT / Met-HeFT)
    Medical condition: Heart Failure
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-002335-17 Sponsor Protocol Number: 2015-602295-01 Start Date*: 2015-11-30
    Sponsor Name:Ethicare GmbH
    Full Title: ORODISPERSIBLE MINITABLETS OF ENALAPRIL IN CHILDREN WITH HEART FAILURE DUE TO DILATED CARDIOMYOPATHY
    Medical condition: Heart Failure due to Dilated Cardiomyopathy
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004849 10056419 Dilated cardiomyopathy LLT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: HU (Completed) NL (Completed) GB (GB - no longer in EU/EEA) AT (Completed) DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2014-002114-23 Sponsor Protocol Number: BAY88-8223/17096 Start Date*: 2015-10-26
    Sponsor Name:Bayer HealthCare AG
    Full Title: A phase II randomized, double-blind, placebo-controlled trial of radium-223 dichloride in combination with exemestane and everolimus versus placebo in combination with exemestane and everolimus whe...
    Medical condition: Metastatic HER2 negative hormone receptor positive breast cancer subjects with bone metastases
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055113 Breast cancer metastatic PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Completed) GB (Completed) ES (Completed) AT (Completed) CZ (Completed) NL (Completed) DE (Completed) BE (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2007-000151-33 Sponsor Protocol Number: rosu01 Start Date*: 2007-04-02
    Sponsor Name:UMCN
    Full Title: Does caffeine reduce rosuvastatin-induced protection against ischemia-reperfusion injury?
    Medical condition: Rosuvastatin is a proven cholesterol lowering medicine. Apart from it’s cholesterol lowering action, rosuvastatin may also increase tolerance against ischemia-reperfusion injury. We hypothesize tha...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10000891 Acute myocardial infarction LLT
    9.1 10023033 Ischemia myocardial LLT
    Population Age: Adults Gender: Male
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2021-002028-19 Sponsor Protocol Number: RH-CARD-Pharma001 Start Date*: 2022-02-01
    Sponsor Name:Department of Cardiology, Copenhagen University Hospital Rigshospitalet
    Full Title: Low-dose dobutamine infusion and single-dose tocilizumab in acute myocardial infarction patients with high risk of cardiogenic shock development – a 2x2 multifactorial, double-blinded, randomized, ...
    Medical condition: Acute Myocardial Infarction with increased risk of Cardiogenic Shock.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10000891 Acute myocardial infarction PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-001247-39 Sponsor Protocol Number: CV185-362 Start Date*: 2017-04-24
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Prospective, Randomized, Open Label, Multi-center Study of the Safety and Pharmacokinetics of Apixaban versus Vitamin K Antagonist or LMWH in Pediatric Subjects with Congenital or Acquired Heart ...
    Medical condition: Congenital or Acquired Heart Disease Requiring Chronic Anticoagulation for Thromboembolism Prevention
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10019273 Heart disease congenital PT
    20.0 10007541 - Cardiac disorders 10007636 Cardiomyopathy PT
    20.0 10007541 - Cardiac disorders 10019276 Heart disease, unspecified LLT
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10037400 Pulmonary hypertension PT
    20.0 10047065 - Vascular disorders 10023320 Kawasaki's disease PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) GB (GB - no longer in EU/EEA) IT (Completed) FI (Completed) AT (Completed) ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-003320-16 Sponsor Protocol Number: CEL-03 Start Date*: 2020-12-23
    Sponsor Name:CeleCor Therapeutics, Inc.
    Full Title: A Phase 3 prospective, blinded, randomized, placebo controlled, international multicenter study to assess the safety and efficacy of a single subcutaneous injection of zalunfiban in subjects with S...
    Medical condition: Subjects with documented STEMI, presenting with persistent ischemic chest pain (>10 minutes) and new ≥2 mm ST-segment elevation in 2 adjacent ECG leads, in whom the total duration of symptoms to di...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10028593 Myocardial disorders HLGT
    20.0 10007541 - Cardiac disorders 10000891 Acute myocardial infarction PT
    20.0 10007541 - Cardiac disorders 10028600 Myocardial ischaemia PT
    21.0 10007541 - Cardiac disorders 10081099 Acute cardiac event PT
    23.1 100000004848 10062084 Platelet aggregation LLT
    20.1 10005329 - Blood and lymphatic system disorders 10050661 Platelet aggregation inhibition PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned) CZ (Trial now transitioned) HU (Trial now transitioned) FR (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 09 16:14:39 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA